Read the study in the context of the treatment decision
Our initiation starts with the disease and current treatment pathway. We identify which patients the company is studying, what alternatives they have, and how meaningful the proposed benefit would be in practice. In a chronic condition, durability, safety, and the burden of repeated administration can influence uptake as much as the response observed at the primary assessment.
We review enrollment criteria, the control arm, randomization and blinding where applicable, the prespecified endpoint, and how long the study followed patients. We read the magnitude and precision of the effect alongside the statistical result. Dropouts, missing data, background therapies, and safety findings can change how confidently that result carries into a broader population. The FDA’s guidance on multiple endpoints explains why the testing plan matters when several outcomes are assessed.
Topline results can answer part of the clinical question. We examine the announced data in light of the protocol and earlier studies, then identify what remains open pending fuller disclosure. ClinicalTrials.gov provides protocol summaries and posted results for registered studies. Competitor comparisons also require care. A trial with a different comparator, patient mix, or follow-up period may report a larger effect without demonstrating superior performance in a head-to-head study.
Model the path to a label investors can underwrite
The regulatory case starts with the evidence needed for a particular indication and jurisdiction. We map disclosed plans for enrollment, readouts, filings, review, and any additional clinical or manufacturing work. Where the company has described regulatory feedback, we use the public record to distinguish what has been agreed from what is still an assumption.
We develop scenarios for a standard development path, a longer path that requires further evidence, and other outcomes supported by the record. An extra study can add trial costs and defer expected cash inflows. It can also shorten the period between a commercial launch and the expiry of a key patent. In the U.S., the FDA Accelerated Approval program can allow approval based on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit, with confirmatory obligations. The applicable pathway and any obligations belong in the program assumptions.
The label matters for the revenue forecast. If pivotal evidence supports only patients who have failed a prior therapy, the base case should begin with that treatment line. We assess separate indications, subpopulations, geographies, and any partner rights at the level supported by disclosed information.
Build the revenue forecast at the indication level
Start with epidemiology, then work toward patients the company could treat. Depending on the indication, the relevant counts are diagnosed patients, patients meeting clinical criteria, those at the appropriate line of treatment, and those who can access the therapy. For an infused or supervised product, site capacity, referral patterns, and treatment time can constrain the launch even where clinical demand is substantial.
We forecast adoption, persistence, retreatment, or treatment courses separately where the economics warrant it. A large eligible population may support a modest commercial opportunity if prescribers have close alternatives or administration is difficult. We compare competitor labels, study results, established standards of care, route of administration, and upcoming development milestones. Those factors can affect the launch curve as well as peak penetration.
A price assumption needs an access assumption. We model net realized price after appropriate gross-to-net deductions where supportable, and consider payer restrictions alongside patient affordability and physician workflow. The CMS coverage determination process illustrates how coverage decisions can be made nationally or locally in Medicare. Evidence and payment arrangements vary by product, setting, and payer, so we test the implications of changes in both access and net price.
Risk-adjust program cash flows and reconcile them to the company
We build an expected cash flow schedule for each material program or indication. It can include remaining development spend, potential milestones, commercial cash flows, royalties, and post-exclusivity erosion. Probabilities and timing reflect the stage and evidence for that specific program. An early signal in a small study supports a different probability assessment from a reproducible result in an adequately controlled pivotal study. We document the judgment and show a range around inputs with unusual uncertainty.
Risk adjustment also affects spending. If a program succeeds at one stage, future trial or launch costs may become more likely. That is different from discounting all forecast revenue by one percentage and assuming every projected cost is certain. Our models account for costs at the relevant stages and consider overlapping infrastructure and spending across indications so shared costs are reflected appropriately.
Program values then roll into the company valuation, adjusted for commercial rights, net cash or debt, shared corporate costs, and the capitalization. We look at how discount rates, approval probability, launch timing, market access, and eventual loss of exclusivity affect value. A rise in program value can coincide with a lower estimate of value per share if development requires materially more equity capital.
Runway depends on the development and financing calendar
We schedule spending against trial starts, enrollment, manufacturing, regulatory work, launch preparation, and recurring corporate costs. Starting with the reported cash position, the model considers debt service, restrictions on cash, licensing commitments, and the terms of any disclosed funding. We distinguish contracted receipts from potential financing or business development proceeds.
For an early-stage company, the runway estimate is especially useful when it shows the cash available at the next decision point and how much room the company has for delays. If the downside case pushes data into a later quarter or starts a second study before results arrive, we quantify the effect on runway and the size and timing of a potential funding gap. Alternative financing cases show what equity issuance, a partnership, or a change in spending could mean for existing shareholders. Each assumption is visible in the model.
Keep the pipeline model current as evidence arrives
A clinical update explains which assumptions the new evidence supports and which still depend on the next milestone. A regulatory meeting might clarify the size of a study while leaving the efficacy assumptions unchanged. A licensing transaction can alter the company’s share of future economics and reduce funding needs. Quarterly reports let us check actual spending and enrollment progress against the plan.
Our independent Helus Pharma initiation and November research update illustrate how AER connects program developments to the financial outlook. The company-sponsored research program brings the same analytical approach to issuer-funded mandates, with the funding relationship disclosed in the published work.
Frequently asked questions
Can AER cover a company without product revenue?
Yes. The model can focus on the pipeline, development costs, disclosed rights, clinical milestones, and financing scenarios. Commercial forecasts and program valuations reflect the evidence and uncertainty at the company’s stage.
How do you value multiple indications for the same therapy?
We forecast each material indication using its own patient population, development requirements, probability, and commercial assumptions. We review overlapping patients, shared costs, and rights before aggregating the program values.
What can a note say when only topline data are available?
It can assess the disclosed result against the trial’s objectives, identify any immediate forecast changes, and specify the evidence still needed. A later update can incorporate the detailed dataset and any resulting changes to the development or commercial outlook.